More Videos
SPECIAL REPORT
- Portfolio Prep for Next Week: 'Don't Get Crazy'
- U.S. Stocks Fall on Dubai Worries
- Black Friday at Best Buy
- Strategists on Dubai: Avoid 'Rash Moves' Now
- Longer Lines, Fuller Carts This Black Friday
- Dubai Stock Market Fear Has 'Legs': Dennis Gartman
- Obama's Emission Reduction Pledge Paints Future for Autos
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- US Shoppers Spent Less Over Black Friday: NRF
- UAE Central Bank Stands by Banks Amid Dubai Crisis
- UAE Markets Seen Limit Down on Monday Open
- Banks With The Biggest Exposure to The UAE
- Dubai's Debt Woes Signal New Era for Creditors
- A Weak IPO Debut for Las Vegas Sands' Macau Unit
- US Treasury Wants Banks to Do More to Ease Mortgages
- Tiger Woods Accepts Full Blame for Car Crash
- Next Week: Cash In Now Or Wait For A Santa Rally?
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
I think I just killed a tree. This morning I printed out the GlaxoSmithKline [GSK
Loading...
()
] and FDA documents that were posted on the agency's Web site ahead of the advisory committee meeting on Avandia safety next Monday. About 700 pages! Nearly as many pages as the new "Harry Potter" book, but not nearly as entertaining.
Actually, I bought the 'Potter' book on CD and haven't started listening to it yet (The narrator, Broadway veteran Jim Dale, by the way, is incredible. Don't know how he does it, but he slips from one character's voice into the next.) I digress. Contained within the documents are the results of a new GSK study (I wonder how much it cost) of the health insurance records of 400,000 diabetics that apparently show Avandia carries no greater heart attack risk than other diabetes drugs. We'll find out on Monday how much weight that carries with the huge panel.
The FDA has put nearly two dozen voting members on the committee for this meeting. The typical panel usually has around eight or 10. Now that the makeup of the committee is public, analysts will be busy checking out each member and trying to predict which way they might vote. At least a couple of senators claim the group is stacked in GSK's favor. The FDA staff's documents say the agency has "considerable concern" about the potential heart attack risk with Avandia, but adds that there are "somewhat inconsistent findings" regarding that risk.
The panel will hear from both sides Monday and then in the late afternoon vote on recommendations that could possibly result in a severe safety warning being put on the Avandia label or maybe even the drug being ordered off the market.
If you want some good bedtime reading go to www.fda.gov. Click on Advisory Committees, then Drugs and then on the Endocrinologic and Metabolic Drugs "Go" tab and you, too, can wipe out a forest.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes